Currently the clinical pipeline of Gluetacs, GT919 and GT929, are in clinical trials for multiple myeloma and non-Hodgkin’s lymphoma respectively. We are providing counseling service for patients with multiple myeloma and non-Hodgkin’s lymphoma.